Active substance
Tropisetron
- SFDA 2
- WHO EML 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NAVOBAN 5MG CAPS | 5 mg | Capsule · Oral use | 5 Blister | SAR 387.90 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| NAVOBAN 5MG-5ML AMP | 1 mg/ml | Injection · Intravenous use | 1 Ampoule | SAR 91.50 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
WHO WHO Model List of Essential Medicines (2025)
- 2.3. Medicines for other common symptoms in palliative care · core
Therapeutic equivalent to ondansetron for Palliative care - 17.2. Antiemetic medicines · core
Therapeutic equivalent to ondansetron for Nausea or vomiting
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.